Effect of TNF inhibitors on arterial stiffness and intima media thickness in rheumatoid arthritis: a systematic review and meta-analysis

[1]  H. Lamb,et al.  Normal and reference values for cardiovascular magnetic resonance-based pulse wave velocity in the middle-aged general population , 2021, Journal of Cardiovascular Magnetic Resonance.

[2]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[3]  P. Chowienczyk,et al.  Do anti TNF-α biologics affect sub-clinical measures of atherosclerosis and arteriosclerosis? A systematic review. , 2020, British journal of clinical pharmacology.

[4]  G. Szűcs,et al.  Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis , 2019, Rheumatology International.

[5]  M. Nurmohamed,et al.  FRI0027 PROGNOSTIC MARKERS FOR PRECLINICAL CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS AND CORRELATION WITH DISEASE ACTIVITY , 2019, Poster Presentations.

[6]  J. Świerkot,et al.  AB0411 TNF ALPHA INHIBITORS INFLUENCE THE CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS , 2019, Abstracts Accepted for Publication.

[7]  P. Jennum,et al.  Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population: A nationwide register study , 2019, Journal of comorbidity.

[8]  J. Paterson,et al.  Causes of Death in Rheumatoid Arthritis: How Do They Compare to the General Population? , 2018, Arthritis care & research.

[9]  C. Turesson,et al.  Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis , 2018, Current therapeutic research, clinical and experimental.

[10]  K. Goetze,et al.  FRI0072 The impact of anti-tnf-therapy on endothelial function in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis , 2018, FRIDAY, 15 JUNE 2018.

[11]  T. Mikuls,et al.  State of the Art Review: Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications , 2018 .

[12]  S. Wray,et al.  The effects of age on pulse wave velocity in untreated hypertension , 2018, Journal of clinical hypertension.

[13]  C. Vlachopoulos,et al.  The effect of TNF-a antagonists on aortic stiffness and wave reflections: a meta-analysis , 2018, Clinical Rheumatology.

[14]  Hossam M. Hammady,et al.  Rayyan—a web and mobile app for systematic reviews , 2016, Systematic Reviews.

[15]  H. Shen,et al.  THU0154 Effects of Etanercept Biomimics on Lipid Profiles in Patients with Rheumatoid Arthritis , 2016 .

[16]  E. Jacobs,et al.  Rheumatologist and Primary Care Management of Cardiovascular Disease Risk in Rheumatoid Arthritis: Patient and Provider Perspectives , 2016, Arthritis care & research.

[17]  M. Nurmohamed,et al.  Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders , 2016, Heart.

[18]  Y. Hong,et al.  Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis , 2015, Journal of Korean medical science.

[19]  R. Płoski,et al.  Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis , 2015, Journal of immunology research.

[20]  C. Vlachopoulos,et al.  Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis , 2015, Clinical Rheumatology.

[21]  G. Kitas,et al.  Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? , 2014, Rheumatology.

[22]  Mahboob Rahman,et al.  Effect of Golimumab on Carotid Atherosclerotic Disease Measures and Cardiovascular Events in Inflammatory Arthritides , 2014, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[23]  P. Giral,et al.  Radial augmentation index is a surrogate marker of atherosclerotic burden in a primary prevention cohort. , 2013, Atherosclerosis.

[24]  Cheuk-Man Yu,et al.  Infliximab is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis — A Randomized Trial , 2012, The Journal of Rheumatology.

[25]  B. Combe,et al.  Etanercept normalises left ventricular mass in patients with rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[26]  D. Morrissey,et al.  The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review. , 2012, Seminars in arthritis and rheumatism.

[27]  M. González-Gay,et al.  Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy , 2012, Mediators of inflammation.

[28]  Lu Gao,et al.  Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data , 2012, The Lancet.

[29]  D. Mozaffarian,et al.  Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. , 2011, The American journal of cardiology.

[30]  K. Amano,et al.  Tocilizumab Monotherapy Reduces Arterial Stiffness as Effectively as Etanercept or Adalimumab Monotherapy in Rheumatoid Arthritis: An Open-label Randomized Controlled Trial , 2011, The Journal of Rheumatology.

[31]  B. Dijkmans,et al.  Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. , 2011, Seminars in arthritis and rheumatism.

[32]  W. Ghali,et al.  Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis , 2011, Arthritis care & research.

[33]  Pierre-Antoine Gourraud,et al.  Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. , 2011, Joint, bone, spine : revue du rhumatisme.

[34]  P. Szodoray,et al.  Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. , 2011, The Israel Medical Association journal : IMAJ.

[35]  E. Nagel,et al.  Unravelling the phenotype of cardiovascular inflammation with magnetic resonance imaging: detecting the change with anti-TNF treatment in patients with rheumatoid arthritis , 2011, Journal of Cardiovascular Magnetic Resonance.

[36]  Michael J Pencina,et al.  Associations of Carotid Artery Intima‐Media Thickness (IMT) With Risk Factors and Prevalent Cardiovascular Disease , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[37]  M. Turiel,et al.  Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. , 2010, Cardiovascular therapeutics.

[38]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[39]  E. Pohanka,et al.  Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab , 2010, Clinical Rheumatology.

[40]  T. Pullar,et al.  Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. , 2009, Rheumatology.

[41]  C. Lodigiani,et al.  Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis , 2009, International journal of general medicine.

[42]  A. Ferrante,et al.  Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid arthritis , 2009, Rheumatology International.

[43]  P. Sidiropoulos,et al.  Sustained improvement of vascular endothelial function during anti‐TNFα treatment in rheumatoid arthritis patients , 2009, Scandinavian journal of rheumatology.

[44]  B. Kirkham,et al.  Infliximab improves vascular stiffness in patients with rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[45]  M. Argyropoulou,et al.  Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. , 2008, Seminars in arthritis and rheumatism.

[46]  Y. Allanore,et al.  Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs , 2008, Expert opinion on pharmacotherapy.

[47]  T. Pincus,et al.  Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis. , 2007, The Journal of rheumatology.

[48]  N. Komai,et al.  Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis , 2007, Modern rheumatology.

[49]  D. Symmons,et al.  Mortality in established rheumatoid arthritis. , 2007, Best practice & research. Clinical rheumatology.

[50]  M. Vitale,et al.  Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. , 2007, Rheumatology.

[51]  S. Gabriel,et al.  Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? , 2007, Annals of the rheumatic diseases.

[52]  Michiel L Bots,et al.  Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies , 2006, Current medical research and opinion.

[53]  D. Grobbee,et al.  Non-invasively measured structural and functional arterial characteristics and coronary heart disease risk in middle aged and elderly men. , 2006, Atherosclerosis.

[54]  P. Libby,et al.  Vascular Biomarkers and Surrogates in Cardiovascular Disease , 2006, Circulation.

[55]  Javier Martín,et al.  Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[56]  G. McColl,et al.  Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. , 2005, Rheumatology.

[57]  J. Aronson.  Biomarkers and surrogate endpoints. , 2005, British journal of clinical pharmacology.

[58]  M. Yıldız,et al.  Increased pulse wave velocity and shortened pulse wave propagation time in young patients with rheumatoid arthritis. , 2004, The Canadian journal of cardiology.

[59]  H. Markus,et al.  Rates and Determinants of Site-Specific Progression of Carotid Artery Intima-Media Thickness: The Carotid Atherosclerosis Progression Study , 2004, Stroke.

[60]  H. Seo,et al.  Aortic pulse wave velocity as an independent marker of coronary artery disease , 2004, Blood pressure.

[61]  G L Freeman,et al.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.

[62]  P. Chowienczyk,et al.  Do anti-tumour necrosis factor- α biologics affect subclinical measures of atherosclerosis and arteriosclerosis? A systematic review , 2020 .

[63]  Takahiro Suzuki,et al.  [Anti-atherosclerotic effects of etanercept in rheumatoid arthritis patients]. , 2012, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[64]  J. Jeng,et al.  Age- and gender-associated determinants of carotid intima-media thickness: a community-based study. , 2012, Journal of atherosclerosis and thrombosis.